PharmaBiome raises CHF 1.75 million to advance preclinical development and welcomes new board members
08.07.2020
PharmaBiome AG, a pioneer in next-generation microbiome therapies, successfully raised new capital in the amount of CHF 1.75 million to bridge to a planned Series A financing. The company also announces the election of Dr. Thomas Meier as Chairman of the Board and Dr. Patrik Forrer as a further new Board member.
 PharmaBiome Team 2020
|
 |
PharmaBiome has secured CHF 1.75 million in bridge financing from current shareholders and new investors, including newly elected members of the board. The new funds will allow the company to advance the preclinical development of its most advanced product PB002 for the treatment of ulcerative colitis (UC) and to strengthen its unique production and lead identification platforms. With the intention of initiating the first pilot clinical trial with PB002 in UC, PharmaBiome has the ambition to emerge as a leading European company in the microbiome field. PharmaBiome also plans to raise a Series A financing to further support its product pipeline and platform technology.
PharmaBiome was both a Venture Kick winner and a Venture Leaders Life Sciences in 2016 and has been one of the TOP 100 Swiss Startups for the last four consecutive years.
PharmaBiome strengthens its Board of Directors
Dr. Thomas Meier has joined the Board as PharmaBiome’s new Chairman. Thomas has a strong track record in the pharmaceutical industry as founder, chief scientific officer, and senior manager. In his last position, he served as CEO of Santhera Pharmaceuticals AG (SIX: SANN) which he successfully advanced from early stages to a fully integrated commercial company. Dr. Patrik Forrer has been elected a Board member of PharmaBiome. Patrik was an instrumental driving force behind the development of designed ankyrin repeat proteins (DARPins) as a novel therapeutic modality. Based on this technology, he co-founded Molecular Partners AG (SIX: MOLN) in 2004 and served the company in various functions, incl. as its first Chairman.
“I am very pleased that with Thomas and Patrik, we have been able to attract highly experienced and visionary minds to our leadership team. Their entrepreneurial spirit coupled with a deep know-how of science and innovation will significantly support our growth ambitions as we move our lead product towards clinical development and strengthen our platform technology,” said Dr. Tomas de Wouters, CEO and co-founder of PharmaBiome. “I am most grateful that we can continue to rely on the leading-edge scientific advice from our founders, who will continue working closely with PharmaBiome.”